NCT07084311View on ClinicalTrials.gov

Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Dentatorubral-Pallidoluysian Atrophy
Interventions
DRUG

nL-ATN1-002

Personalized antisense oligonucleotide

Trial Locations (1)

96817

Hawaii Pacific Neuroscience, Honolulu

Sponsors
All Listed Sponsors
collaborator

Hawaii Pacific Neuroscience

UNKNOWN

lead

n-Lorem Foundation

OTHER